Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC, doing business as Merck, is a pharmaceutical manufacturer that supplies vaccines, specialty therapeutics, and medical countermeasures to federal agencies as a prime contractor on a full-and-open (non-set-aside) posture, with 890 prime awards and a combined potential value of $63.17 billion across 891 total federal actions (prime and sub). Merck is a subsidiary of Schering Plough Corporation and competes across pharmaceutical procurement vehicles spanning the Department of Veterans Affairs, Centers for Disease Control and Prevention, Department of Health and Human Services, and Department of Defense.

Merck's federal footprint centers on vaccine and pharmaceutical product supply. The company holds a $5.84 billion Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs with the Department of Veterans Affairs, awarded June 1, 2025, and extending through May 31, 2030, from which it fulfills delivery orders for specialty therapeutics including WINREVAIR (sotatercept-csrk) for pulmonary hypertension and Welireg (belzutifan) for renal cell carcinoma across multiple Veterans Integrated Service Networks. Recent VA delivery orders on this schedule include a $336.6 million emergency WINREVAIR order (March 10, 2025, VISN 22) and recurring orders for Welireg ranging from $20,000 to $66,000 per order. Merck also holds a $4.48 billion Vaccines for Children (VFC) multiple-award indefinite delivery contract with the CDC, awarded April 1, 2026, extending through March 31, 2027, for pediatric vaccine procurement, and a $66.01 million adult vaccines indefinite delivery contract with the CDC, awarded July 1, 2025, through June 30, 2026. The company received a $173.6 million sole-source delivery order from the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (September 30, 2024) for ERVEBO Zaire ebolavirus vaccine procurement, including vendor-managed inventory storage and bioreactor manufacturing process development with a 120-month performance period. A $72.5 million Blanket Purchase Agreement for Welireg with the National Acquisition Center, awarded July 12, 2025, extends through July 11, 2027, and incorporates Public Law pricing update mechanisms. Merck also holds a $39.1 million Other Transaction Agreement for Prototype with the Joint PEO Chemical and Biological Defense, awarded March 14, 2025, for development of molnupiravir as an oral therapeutic for Venezuelan Equine Encephalitis Virus.

Customer concentration skews heavily toward healthcare and immunization programs. The CDC Pittsburgh accounts for 31 awards with $43.36 billion in combined potential value (69% of all potential value), anchored by the multi-billion-dollar VFC and adult vaccines contracts. The VA Veterans Health Administration, Veterans Integrated Service Network 12, holds 15 awards with $14.98 billion combined potential value, driven by the $5.84 billion FSS-61-IB schedule contract. The HHS Office of the Assistant Secretary for Preparedness and Response accounts for 6 awards and $756.9 million combined potential value, led by the ERVEBO vaccine procurement contract. On award count, the Defense Logistics Agency leads with 308 awards, but these are materially smaller orders; HHS Office of the Assistant Secretary for Administration places 144 awards with only $11.4 million combined potential value, reflecting high-volume, low-dollar micro-purchases or standing order activity.

Merck's principal contract vehicles include the $5.84 billion VA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) with 133 delivery orders and $94 million in combined potential value, the Federal Supply Schedule V797P5893X with 209 task orders and $10.6 million combined potential value, and a Basic Ordering Agreement (V797P5230J) with 20 task orders. The company operates predominantly as a prime contractor (100% of awards by count), with minimal sub-award activity—one grant sub-award as a sub-recipient under Johns Hopkins University for a Phase III clinical trial on survorexant versus placebo for insomnia in opioid use disorder (awarded June 5, 2025).

Activity has grown from 3 awards in 2023 to 35 in 2025, with 15 awards recorded in 2026 year-to-date through early July. Within the next twenty-four months, five awards with combined potential value of $297.9 million reach ultimate completion, representing moderate recompete exposure—primarily the adult vaccines contracts and certain VA delivery orders with rolling completion dates through mid-2027.

SCI-reported service-contract invoicing totaled $3.7 million across FY2022–FY2024 (FY2022: $1.2 million, FY2023: $1.2 million, FY2024: $1.3 million), delivered by approximately 0.1 FTEs per fiscal year. Government-paid rates for SCI-reportable labor ran a median of $8,880.11 per hour, with a range from the 10th percentile at $8,294.57 per hour through the 90th percentile at $10,804.97 per hour. Across SCI-reportable prime contracts, Merck self-performed 100% of labor (zero sub-hours share). The SCI subset captures only vaccine storage and rotation services delivered to the CDC (the $13 million CDC Pittsburgh vaccine storage IDV awarded September 16, 2021); the bulk of Merck's federal revenue derives from product supply under GSA schedules and CDC vaccine contracts, which fall outside the SCI reporting threshold.

Merck is structured as a for-profit manufacturer of goods with named subsidiaries Biomark LLC and Cidara Therapeutics Inc. The company competes across the full pharmaceutical and vaccine manufacturing portfolio without SBA certifications (8(a), HUBZone, SDVOSB, WOSB) and leverages established federal relationships spanning 46 distinct customer agencies. Recent growth in award volume and the maturation of multi-billion-dollar vaccine indefinite delivery vehicles position Merck as a cornerstone supplier to federal public health and veterans healthcare systems.